Translating Python Biology to the Mammalian Heart
将Python生物学转化为哺乳动物心脏
基本信息
- 批准号:8704090
- 负责人:
- 金额:$ 40.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-01 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdrenergic AgentsAffectAftercareAmericanAnimal ModelAnimalsAutophagocytosisBiologyBloodCardiacCardiac MyocytesCardiovascular DiseasesDataDiseaseEatingExerciseExhibitsFatty AcidsFatty acid glycerol estersFree RadicalsGene ExpressionGenesGoalsGrowthHeartHeart DiseasesHeart HypertrophyIn VitroKnockout MiceLeadLipidsMammalsMediatingMetabolicMitochondriaMusMyocardial InfarctionOrganPathologicPathway interactionsPeroxisome Proliferator-Activated ReceptorsPhenotypePhysiologicalPlasmaPreventiveProcessPythonsRattusRoleSignal PathwaySignal TransductionSocietiesStimulusTestingTherapeuticTranslatingTriglyceridesadrenergicbasedrug discoveryeconomic costin vivomulticatalytic endopeptidase complexnovelpreventpublic health relevanceresearch studyresponsewater channel
项目摘要
DESCRIPTION (provided by applicant): Given the proven potential for uncovering novel biology and for drug discovery by studying animals that have evolved extreme biology to survive, we have recently employed the post-prandial Burmese python as an animal model to discover novel pathways of beneficial cardiac adaptation. An infrequent feeder, the Burmese python exhibits a ~40-fold increase in overall metabolic rate and a 160-fold increase in plasma triglycerides within a day of eating a meal that can equal its body mass.1,2 This extreme metabolic demand activates potent, rapid and reversible organ growth, including physiologic cardiac hypertrophy.1,3 We found that post-prandial cardiac hypertrophy is accompanied by cardioprotective mechanisms that activate beneficial changes in gene expression and, despite very high circulating triglycerides, prevent cardiac lipid accumulation. Instead, the heart increases expression and activity of genes involved in lipid handling, mitochondrial oxidative capacity, and free radical scavenging.3 Importantly, we identified a novel combination of 3 fatty acids (FAs) (myristic [C14:0; 40 ¿ M], palmitic [C16:0;100 ¿M] and palmitoleic [C16:1; 7.5
¿ M] acids) in post-prandial python plasma that when administered to either pythons or mice promotes beneficial cardiac adaptation3 with no signs of pathologic lipid signaling. This appears to be independent of PPAR signaling; these and other data lead us to believe that this pathway is novel. Moreover, we found that an aqua-glyceroporin gene, aquaporin 7 (AQP7), is the most potently activated gene in rat cardiac myocytes treated with these FAs and its expression is upregulated in hearts of FA-treated mice. We have made cardiac myocyte-specific AQP7 null mice and have found that they have an exaggerated pathological response to adrenergic stimulation. These data, in conjunction with bi-directional responses of the AQP7 gene in exercise and disease, suggest that AQP7 may be mediating some of the cardioprotective mechanisms described above. Based on these data, the goals of this project are three-fold. First, we will elucidate cardioprotective mechanisms utilized by the python and translate them to mammals. Second, many aspects of the python post- prandial cardiac responses resemble the beneficial mammalian cardiac response to exercise. Therefore, we will explore the preventive and therapeutic potential of the FAs before or after a pathologic cardiac stimulus, respectively. We will define the mechanisms underlying the ability of these FAs to modify disease. Third, we will define the mechanisms by which the python heart undergoes regression subsequent to hypertrophic growth. The results of these proposed experiments should suggest novel signaling pathways that may lead to therapeutics for cardiovascular disease.
描述(由申请人提供):考虑到通过研究进化出极端生存生物学的动物来发现新的生物学和药物发现的潜力,我们最近采用餐后缅甸蟒蛇作为动物模型来发现有益心脏适应的新途径。缅甸蟒蛇是一种不经常进食的动物,在一天内吃下相当于其体重的食物,其总体代谢率增加约40倍,血浆甘油三酯增加160倍这种极端的代谢需求激活了强大的、快速的和可逆的器官生长,包括生理性心脏肥大我们发现餐后心脏肥厚伴随着心脏保护机制,激活基因表达的有益变化,尽管循环甘油三酯非常高,但仍可防止心脏脂质积累。相反,心脏增加了与脂质处理、线粒体氧化能力和自由基清除有关的基因的表达和活性重要的是,我们发现了3种脂肪酸(FAs)的新组合(肉豆蔻酸[C14:0; 40¿M],棕榈酸[C16:0;100¿M]和棕榈烯酸[C16:1; 7.5]
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leslie Anne Leinwand其他文献
Leslie Anne Leinwand的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leslie Anne Leinwand', 18)}}的其他基金
Molecular Characterization of Cardiomyopathy Mutations in Human Cardiac Myosin
人心肌肌球蛋白心肌病突变的分子特征
- 批准号:
8584984 - 财政年份:2013
- 资助金额:
$ 40.7万 - 项目类别:
Molecular Characterization of Cardiomyopathy Mutations in Human Cardiac Myosin
人心肌肌球蛋白心肌病突变的分子特征
- 批准号:
9058602 - 财政年份:2013
- 资助金额:
$ 40.7万 - 项目类别:
Molecular Characterization of Cardiomyopathy Mutations in Human Cardiac Myosin
人心肌肌球蛋白心肌病突变的分子特征
- 批准号:
8723276 - 财政年份:2013
- 资助金额:
$ 40.7万 - 项目类别:
Molecular Characterization of Cardiomyopathy Mutations in Human Cardiac Myosin
人心肌肌球蛋白心肌病突变的分子特征
- 批准号:
8843945 - 财政年份:2013
- 资助金额:
$ 40.7万 - 项目类别:
Mechanisms of myopathy caused by mutations in the myosin rod
肌球蛋白杆突变引起的肌病机制
- 批准号:
7260196 - 财政年份:2007
- 资助金额:
$ 40.7万 - 项目类别:
Mechanisms of myopathy caused by mutations in the myosin rod
肌球蛋白杆突变引起的肌病机制
- 批准号:
7406843 - 财政年份:2007
- 资助金额:
$ 40.7万 - 项目类别:
Mechanisms of myopathy caused by mutations in the myosin rod
肌球蛋白杆突变引起的肌病机制
- 批准号:
7587246 - 财政年份:2007
- 资助金额:
$ 40.7万 - 项目类别:
Mechanisms of myopathy caused by mutations in the myosin rod
肌球蛋白杆突变引起的肌病机制
- 批准号:
7789632 - 财政年份:2007
- 资助金额:
$ 40.7万 - 项目类别:
DENVER CARDIOVASCULAR HEALTH EDUCATION ALLIANCE, PHASE I
丹佛心血管健康教育联盟,第一阶段
- 批准号:
6663838 - 财政年份:2002
- 资助金额:
$ 40.7万 - 项目类别:
Developmental Myosin Heavy Chain Regulation and Function
发育性肌球蛋白重链调节和功能
- 批准号:
6732009 - 财政年份:2002
- 资助金额:
$ 40.7万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 40.7万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 40.7万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 40.7万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 40.7万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 40.7万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 40.7万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 40.7万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 40.7万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 40.7万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 40.7万 - 项目类别:














{{item.name}}会员




